Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
about
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunctionToxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection.Anthracyclines and the heart.Cardiotoxicity of cancer therapy.Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animalsChemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligasesPredicting and preventing the cardiotoxicity of cancer therapy.A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.Toxicoproteomics: new paradigms in toxicology research.The role of anthracyclines in the treatment of early breast cancer.Cardiomyopathy associated with cancer therapy.Advanced heart failure due to cancer therapy.Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.Cardiac spheroids as promising in vitro models to study the human heart microenvironment.New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.Doxorubicin (adriamycin) cardiomyopathy.Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Evaluation of the in vitro antiproliferative properties of four novel anthracyclines YM1, 3, 4 and 6 in human leukemia cell lines.Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection.Cardiotoxic effects of anthracyclines.Toxic cardiomyopathy due to doxorubicin.Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy.Abnormal Ultrasonic Tissue Characterization of the Myocardium in Children Receiving Doxorubicin for Cancer Therapy.Synthesis and characterization of smart N-isopropylacrylamide-based magnetic nanocomposites containing doxorubicin anti-cancer drug.Tumor primitivo ectodérmico pancreático: relato de caso
P2860
Q26743433-304F46F6-9A5F-401C-BD8B-A261263A48D7Q27027354-899EBF2B-C0A5-4929-8085-7FDB213CBC0CQ30446453-2DF7B128-D22F-4E02-86B0-E8DF340F18AAQ33204056-97EF43CD-FEDD-48A2-A39F-E184C6E6D157Q33613628-49D17EDE-8396-4A1C-A93D-D1DE4D55523CQ33704056-BD4C882B-7713-45D9-AD20-066BA25124D9Q34037001-E8D1AF88-5102-4317-BA9E-BC95CA9448D2Q34247662-208161F0-F48F-480E-8BAF-2B012D9FA3C2Q34659375-E842A906-FFD4-4B4C-9480-C9BC0CCD8767Q35855914-8722DC67-1F66-4B20-BC50-ABC71C2397A3Q36772298-B7E541F1-C21F-4183-99DE-B2AF955E5FDFQ37230408-57661CD1-6E9E-4E59-BE66-5DE205ED0795Q37629634-A80B556D-540D-4CDA-93F5-E90E5A1C1A8DQ37696489-853472A8-7DE5-4737-926B-6E2E633724E6Q38207452-D956B7A4-F037-465C-AEC0-E3707F0AE5ACQ38242641-78670057-01C2-4A5A-9439-C3CD7A130BFEQ38357704-2BA1FE31-112A-4E98-93EB-0BBC95D5F9F7Q38406251-4E0873FF-CC69-4B63-9D1F-D1997F997987Q38642910-ECB19E89-4C97-452A-845F-F0F67F10EF93Q38647934-454AD133-6DE6-4793-A4F5-AB7C24A94D18Q39005990-CF52AEB9-F931-4B32-952F-0F5BD1D4A0DEQ40162046-7C7271B4-A8C1-4B71-8910-60C4A6CADE7EQ40809782-65DF43CF-6BB2-454C-9238-EB9E82B91495Q41105379-47831255-C22F-4F84-86EF-6E58935CCE2FQ41599563-EFD7ED2B-57BA-479C-B109-7F74844F9611Q42196156-9BDB3CE0-F3E1-47D2-8833-68D0EEAFEFB3Q42254435-A12FB90B-62CD-4497-8DCA-720611790C8BQ42258412-6D8D150F-B700-4778-ABC6-D05049D3F2E6Q44063021-893BB603-EE76-43DF-A127-E01C4CEFCCB5Q46835198-B9E5B93A-A02B-4B09-B061-CF977AF80FB0Q51295671-D54E2079-D6CC-4F09-8CE8-A962F8E7D414Q52068644-BC8090E5-BC89-4C0B-B8E6-345BA3C8B857Q53098199-711BCA40-2AF0-4308-94B6-5A53C5706F96Q58861092-AC32195C-5131-418D-B34E-DCEFE0A92DE7
P2860
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@en
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@nl
type
label
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@en
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@nl
prefLabel
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@en
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@nl
P2093
P1476
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
@en
P2093
Billingham ME
Bristow MR
Daniels JR
P304
P356
10.1016/0002-8703(81)90096-X
P407
P577
1981-10-01T00:00:00Z